Skip to content



Slynd is contraindicated in females with renal impairment, adrenal insufficiency, a presence or history of cervical cancer or progestin sensitive cancers, liver tumors (benign or malignant) or hepatic impairment, and undiagnosed abnormal uterine bleeding.

Warnings and Precautions
Slynd has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk females. Check serum potassium levels prior to starting treatment and during the first treatment cycle in females receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium concentration. Consider monitoring serum potassium concentration in females at increased risk for hyperkalemia i.e., those females who take a strong CYP3A4 inhibitor long-term and concomitantly with Slynd. Monitor females taking Slynd who later develop conditions and/or begin medication that put them at an increased risk for hyperkalemia.

Thromboembolic Disorders:
Discontinue Slynd if a thromboembolic event occurs and consider discontinuing Slynd in case of prolonged immobilization due to surgery or illness. When prescribing Slynd, consider the increased risk of thromboembolism inherent in the postpartum period and in females with a history of thromboembolism.

Bone Loss:
Treatment with Slynd leads to decreased estradiol serum levels. It is unknown if this may cause a clinically relevant loss of bone mineral density.

Ectopic Pregnancy:
Be alert to the possibility of ectopic pregnancy in females who become pregnant or complain of lower abdominal pain while on Slynd.

Risk of Hyperglycemia in Patients with Diabetes:
Females with diabetes may be at greater risk of hyperglycemia and may require additional medication adjustments or monitoring. Progestins, including Slynd, may decrease insulin sensitivity.

Bleeding Irregularities and Amenorrhea:
Females may experience irregular bleeding or amenorrhea, especially during the first three months of use. If bleeding persists, occurs after previously regular cycles, or if scheduled bleeding does not occur, evaluate for possible causes such as pregnancy or malignancy.

Adverse Reactions
Most common adverse reactions (>1%) are: acne, metrorrhagia, headache, breast pain, weight increased, dysmenorrhea, nausea, vaginal hemorrhage, decreased libido, breast tenderness, irregular menstruation. To report SUSPECTED ADVERSE REACTIONS, contact Exeltis USA, Inc. at 1-877-324-9349 or FDA at 1-800-FDA-1088 or

Drug Interactions
Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of Slynd or increase breakthrough bleeding. Counsel patients to use a back-up or alternative non-hormonal method of contraception when enzyme inducers are used with Slynd and to continue back-up non-hormonal contraception for 28 days after discontinuing the enzyme inducer. Drugs or products that inhibit CYP3A4 may increase Slynd systemic exposure.

Discontinue Slynd if pregnancy occurs.
Counsel patients that Slynd does not protect against HIV-infection (AIDS) and other sexually transmitted infections.

Indications and Usage:
Slynd (drospirenone) tablets are a progestin, indicated for females of reproductive potential to prevent pregnancy.

1. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Acc J Contracept. 2016;7:43-52. doi: 10.2147/OAJC.S85565

2. Slynd [package insert]. Exeltis USA, Inc.; Florham Park, NJ; 2019.

3. Data on file. Exeltis USA, Inc.; Florham Park, NJ; 2019.

4. Fuhrmann U, Krattenmacher R, Slater ED, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251

5. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017:8 (47): 83334-83342.

6. Vroonen L, Cavalier E, Vranken L, et al. Influence of drospirenone on renin-angiotensin-aldosterone system evaluation. Endocrine Abstracts. 2011;26:12.

7. Slopien R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Review. 2018;17(1):1-4. doi: 10.5114/pm.2018.74895

8. Greer JB, Modugno F, Allen G, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.

9. Batur P. Female contraception. Cleveland Clinic Center for Continuing Education. Published December 2016.

10. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis Eur J Prev Cardiol. 2018;25(10):1042-1052. doi: 10.1177/2047487318774847.

11. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016:93(4): 303-309.